Sarah C Sim

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
    S C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 13:1-11. 2013
  2. ncbi Association between CYP2C19 polymorphism and depressive symptoms
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Am J Med Genet B Neuropsychiatr Genet 153:1160-6. 2010
  3. ncbi The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Genomics 4:278-81. 2010
  4. ncbi A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Clin Pharmacol Ther 79:103-13. 2006
  5. ncbi Databases in the area of pharmacogenetics
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Mutat 32:526-31. 2011
  6. ncbi Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
  7. ncbi Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177, Stockholm, Sweden
    Pharmacol Ther 116:496-526. 2007
  8. ncbi The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives
    Sarah C Sim
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Methods Mol Biol 320:183-91. 2006
  9. ncbi CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenet Genomics 15:625-31. 2005
  10. ncbi Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Biophys Res Commun 396:90-4. 2010

Detail Information

Publications17

  1. ncbi Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
    S C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenomics J 13:1-11. 2013
    ....
  2. ncbi Association between CYP2C19 polymorphism and depressive symptoms
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Am J Med Genet B Neuropsychiatr Genet 153:1160-6. 2010
    ..0001). Our results suggest for the first time that the CYP2C19 polymorphism might be of importance for depressive symptoms, as here shown for older European adults...
  3. ncbi The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Genomics 4:278-81. 2010
    ..Thus, the CYP-allele website offers a rapid online publication of new alleles, as well as providing an overview of peer-reviewed data...
  4. ncbi A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm
    Clin Pharmacol Ther 79:103-13. 2006
    ..A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background...
  5. ncbi Databases in the area of pharmacogenetics
    Sarah C Sim
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Hum Mutat 32:526-31. 2011
    ..Here, we review the databases that provide useful information in this respect, of benefit for the development of the pharmacogenomic field...
  6. ncbi Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden
    Eur J Clin Pharmacol 64:1175-9. 2008
    ..The aim of this study was to compare the impact of the CYP2C19*17 allele on omeprazole single-dose kinetics with escitalopram exposure at steady state in volunteers genotyped as either CYP2C19*17/*17 or CYP2C19*1/*1...
  7. ncbi Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177, Stockholm, Sweden
    Pharmacol Ther 116:496-526. 2007
    ....
  8. ncbi The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives
    Sarah C Sim
    Division of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
    Methods Mol Biol 320:183-91. 2006
    ..The CYP allele Web site offers a rapid on-line publication of new alleles, provides an overview of peer-reviewed data, and serves as a form of quality control on research on new alleles...
  9. ncbi CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele
    Sarah C Sim
    Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Pharmacogenet Genomics 15:625-31. 2005
    ..The relatively high level of CYP3A7 protein expression detected in a subset of adult livers may be relevant with respect to the metabolism of exogenous and endogenous substrates, such as retinoic acid and dehydroepiandrosterone...
  10. ncbi Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Biochem Biophys Res Commun 396:90-4. 2010
    ..In this review we give a background and description of this work as well as the important implications for future medicine...
  11. ncbi New approaches and applications in chemical biology
    Alvin Gomez
    Division of Molecular Toxicology, IMM, Karolinska Institutet, SE-171 77 Stockholm, Sweden
    Drug News Perspect 17:594-605. 2004
    ..At the meeting, 73 different lectures were presented and about 240 posters were shown. This review discusses most of the lectures presented at the Symposium...
  12. ncbi Institutional profile: Karolinska Institutet
    Erik Eliasson
    Karolinska Institutet, Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Pharmacogenomics 13:1887-91. 2012
    ..Furthermore, the recently opened Center for Hematology and Regenerative Medicine, with a clear translational emphasis, offers an opportunity for studying drug metabolism and toxicity in vitro by use of human hepatocytes...
  13. ncbi Pharmacogenomic biomarkers: new tools in current and future drug therapy
    Sarah C Sim
    Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institute, 171 77 Stockholm, Sweden
    Trends Pharmacol Sci 32:72-81. 2011
    ..We also discuss the use of these biomarkers in drug development and address the impact on personalized drug prescription, including opportunities and bottlenecks...
  14. ncbi Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database
    Sarah C Sim
    Section for Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
    Methods Mol Biol 987:251-9. 2013
    ..Here, we provide an update of the CYP-allele database and the associated nomenclature...
  15. ncbi Intronic polymorphisms of cytochromes P450
    Magnus Ingelman-Sundberg
    Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE 17177 Stockholm, Sweden
    Hum Genomics 4:402-5. 2010
    ....
  16. ncbi Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression
    Susanne Löfgren
    Safety Assessment, AstraZeneca Research and Development, Sodertalje, Sweden
    Drug Metab Dispos 36:955-62. 2008
    ....
  17. ncbi Coffee, myocardial infarction, and CYP nomenclature
    Magnus Ingelman-Sundberg
    JAMA 296:764-5; author reply 765-6. 2006